Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer.

Abstract

Background:

Breast cancer (BC) is the most common malignant disease worldwide. Although the survival rate is improved in recent years, the prognosis is still bleak once recurrence and metastasis occur. It is vital to investigate more efficient biomarkers for predicting the metastasis and relapse of BC. DYNLT1 has been reported that participating in the progression of multiple cancers. However, there is still a lack of study about the correlation between DYNLT1 and BC.

Methods:

In this study, we evaluated and validated the expression pattern and prognostic implication of DYNLT1 in BC with multiple public cohorts and BC tumor microarrays (TMAs) of paraffin-embedded tissues collected from the Affiliated Hospital of Jining Medical University. The response biomarkers for immune therapy, such as tumor mutational burden (TMB), between different DYNLT1 expression level BC samples were investigated using data from the TCGA-BRCA cohort utilizing public online tools. In addition, colony formation and transwell assay were conducted to verify the effects of DYNLT1 in BC cell line proliferation and invasion.

Results:

The results demonstrated that DYNLT1 overexpressed in BC and predicted poor relapse-free survival in our own BC TMA cohort. In addition, DYNLT1 induced BC development by promoting MDA-MB-231 cell proliferation migration, and metastasis.

Conclusion:

Altogether, our findings proposed that DYNLT1 could be a diagnostic and prognostic indicator in BC.

• Authors: Sen Miao, Gaoda Ju, Chonghua Jiang, Bing Xue, Lihua Zhao, Rui Zhang, Han Diao, Xingzhou Yu, Linlin Zhang, Xiaozao Pan, Hua Zhang, Lijuan Zang, Lei Wang, Tianhao Zhou
• Journal: Frontiers in medicine (Front Med (Lausanne)) Vol. 10 Pg. 1167676 ( 2023) ISSN: 2296-858X [Print] Switzerland
• PMID: 37081842 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 Miao, Ju, Jiang, Xue, Zhao, Zhang, Diao, Yu, Zhang, Pan, Zhang, Zang, Wang and Zhou.